Azacitidine Injection
Bristol Myers Squibb Co. · Available
Open FDA's page for this record- Update type
- Reverified
- Initial posting date
- 12/18/2020
- Package NDC
- 59572-102-01
- Generic name
- Azacitidine Injection
- Contact info
- 1-888-423-5436
- Availability
- Available
- Update date
- 09/15/2026
- Dosage form
- Injection
- Presentation
- Vidaza, Injection, 100 mg (NDC 59572-102-01)
- Company name
- Bristol Myers Squibb Co.
- Status
- Current
- Therapeutic category
- Oncology
- Harmonized identifiers (openFDA)
- Application number
- NDA050794
- Brand name
- VIDAZA
- Generic name
- AZACITIDINE
- Manufacturer name
- Celgene Corporation
- Product NDC
- 59572-102
- Product type
- HUMAN PRESCRIPTION DRUG
- Route
- INTRAVENOUS, SUBCUTANEOUS
- Substance name
- AZACITIDINE
- RxCUI
- 485246, 545206
- SPL ID
- 8cba79e2-11fa-4eb9-87e7-827ca781fbf3
- SPL set ID
- 3495a71a-cc04-4776-851f-f185956f32af
- Package NDC
- 59572-102-01
- Nui
- N0000000233, N0000175595
- Pharm class moa
- Nucleic Acid Synthesis Inhibitors [MoA]
- Pharm class epc
- Nucleoside Metabolic Inhibitor [EPC]
- UNII
- M801H13NRU